0001209191-23-039711.txt : 20230626 0001209191-23-039711.hdr.sgml : 20230626 20230626163111 ACCESSION NUMBER: 0001209191-23-039711 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230625 FILED AS OF DATE: 20230626 DATE AS OF CHANGE: 20230626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McClung David Mark CENTRAL INDEX KEY: 0001811505 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 231042767 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001811505 McClung David Mark C/O SANGAMO THERAPEUTICS, INC. 7000 MARINER BLVD. BRISBANE CA 94005 0 1 0 0 EVP, Chief Operating Officer 0 Common Stock 2023-06-25 4 F 0 11528 1.19 D 211321 D Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 25, 2023 of $1.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. Includes: (a) 21,812 shares resulting from the June 25, 2023 final vesting installment of the Reporting Person's June 25, 2020 RSU grant, (b) 38,982 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (d) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. David Mark McClung, by /s/ Ron A. Metzger, Attorney-in-Fact 2023-06-26